Patents by Inventor Donna Armentano
Donna Armentano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8758761Abstract: In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.Type: GrantFiled: September 30, 2008Date of Patent: June 24, 2014Assignees: University of Florida Research Foundation, Inc., Genzyme CorporationInventors: Mark A. Atkinson, Scott Eisenbeis, Donna Armentano, Abraham Scaria, Tracey Lodie
-
Publication number: 20110212529Abstract: The invention is directed to novel combinations of muscle-specific enhancers and promoter elements useful for achieving persistent expression in the muscle or myocyctes. The muscle-specific promoter elements are derived from a muscle creatine kinase promoter, a troponin I promoter, a skeletal alpha-actin promoter, or a desmin promoter. The muscle-specific enhancer elements are derived from either troponin I internal regulatory elements, muscle creatine kinase enhancers, or desmin enhancers.Type: ApplicationFiled: March 12, 2007Publication date: September 1, 2011Inventors: David Souza, Donna Armentano
-
Publication number: 20100322894Abstract: In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.Type: ApplicationFiled: September 30, 2008Publication date: December 23, 2010Inventors: Mark A Atkinson, Scott Eisenbeis, Donna Armentano, Abraham Scaria, Tracey Lodie
-
Publication number: 20090162345Abstract: In accordance with the subject invention, anti-thymocyte globulin (ATG) can be used to modulate a patient's immune response in order to prevent and/or delay the onset or the progression of type 1 diabetes. ATG treatment augments CD4+CD25+ cell frequencies and their functional activities.Type: ApplicationFiled: November 29, 2006Publication date: June 25, 2009Inventors: Mark A. Atkinson, Gregory Simon, Clive Henry Wasserfall, Abraham Scaria, Desmond A. Schatz, Donna Armentano, Srinivas Shankara
-
Publication number: 20080070297Abstract: The invention is directed to novel combinations of liver specific enhancers and promoter elements for achieving persistent transgene expression in the liver. The liver specific enhancer elements may be derived from either the human serum albumin, prothrombin, ?-1microglobulin or aldolase genes in single copies or in multimerized from linked to elements derived from the cytomegalovirus intermediate early (CMV), ?-1-antitrypsin or albumin promoters. In a preferred embodiment of the invention, an adenoviral vector comprising a liver specific enhancer/promoter combination operably linked to a transgene is administered to recipient cells. In other embodiments of the invention, adeno-associated viral vectors, retroviral vectors, lentiviral vectors or a plasmid comprising the liver specific enhancer/promoter combination linked to a transgene is administered to recipient cells. Also within the scope of the invention are promoter elements derived from the human prothrombin gene and the ?-fibrinogen gene.Type: ApplicationFiled: November 13, 2007Publication date: March 20, 2008Applicant: GENZYME CORPORATIONInventors: David SOUZA, Donna ARMENTANO, Samuel WADSWORTH
-
Patent number: 7318919Abstract: Gene Therapy vectors, which are especially useful for cystic fibrosis, and methods for using the vectors are disclosed.Type: GrantFiled: June 3, 2002Date of Patent: January 15, 2008Assignee: Genzyme CorporationInventors: Richard Gregory, Donna Armentano, Larry A. Couture, Alan E. Smith
-
Patent number: 7312324Abstract: The invention is directed to novel combinations of liver specific enhancers and promoter elements for achieving persistent transgene expression in the liver. The liver specific enhancer elements may be derived from either the human serum albumin, prothrombin, ?-1microglobulin or aldolase genes in single copies or in multimerized form linked to elements derived from the cytomegalovirus intermediate early (CMV), ?-1-antitrypsin or albumin promoters. In a preferred embodiment of the invention, an adenoviral vector comprising a liver specific enhancer/promoter combination operably linked to a transgene is administered to recipient cells. In other embodiments of the invention, adeno-associated viral vectors, retroviral vectors, lentiviral vectors or a plasmid comprising the liver specific enhancer/promoter combination linked to a transgene is administered to recipient cells. Also within the scope of the invention are promoter elements derived from the human prothrombin gene and the ?-fibrinogen gene.Type: GrantFiled: May 6, 2002Date of Patent: December 25, 2007Assignee: Genzyme CorporationInventors: David W. Souza, Donna Armentano, Samuel C. Wadsworth
-
Publication number: 20050107318Abstract: Evidence is emerging that lipid accumulation in the liver and the muscle contributes to insulin resistance in type II diabetes and the metabolic syndrome (1). This has prompted an investigation of the relationship between lipid accumulation in the liver, serum triglyceride levels, and glucose disposal. These studies demonstrate that liver fat positively correlated to fasting triglyceride levels and negatively correlated to glucose diposal (2). Therefore, strategies to prevent lipid accumulation in liver would have therapeutic value for treatment of type II diabetes, metabolic syndrome and non-alcoholic fatty liver disease. The invention described here relates to continuous administration of GLP-1 or its analogs obtained by either gene or cell therapy that results in reduction serum triglycerides and reduction of lipid accumulation in the liver for treatment of type II diabetes, the metabolic syndrome or non-alcoholic fatty liver disease.Type: ApplicationFiled: November 17, 2003Publication date: May 19, 2005Inventors: Samuel Wadsworth, Donna Armentano, Richard Gregory, Geoffrey Parsons
-
Publication number: 20040143104Abstract: Compositions, expression vectors and host cells comprising nucleic acid which encodes a precursor glucagon-like peptide 1 (GLP-1) comprising mammalian GLP-1 linked to a heterologous signal sequence are encompassed by the present invention. The invention also relates to a method of promoting insulin production in an individual comprising administering to the individual an effective amount of a nucleic acid encoding a precursor GLP-1. The present invention also relates to a method of treating an individual having a blood sugar defect (e.g., type I or type II diabetes), comprising administering to the individual an effective amount of a nucleic acid encoding the precursor GLP-1.Type: ApplicationFiled: November 17, 2003Publication date: July 22, 2004Inventors: Samuel C. Wadsworth, Donna Armentano, Richard J. Gregory, Geoffrey Parsons
-
Publication number: 20040002468Abstract: Compositions, expression vectors and host cells comprising nucleic acid which encodes a precursor glucagon-like peptide 1 (GLP-1) comprising mammalian GLP-1 linked to a heterologous signal sequence are encompassed by the present invention. The invention also relates to a method of promoting insulin production in an individual comprising administering to the individual an effective amount of a nucleic acid encoding a precursor GLP-1. The present invention also relates to a method of treating an individual having a blood sugar defect (e.g., type I or type II diabetes), comprising administering to the individual an effective amount of a nucleic acid encoding the precursor GLP-1.Type: ApplicationFiled: August 7, 2002Publication date: January 1, 2004Applicant: Genzyme CorporationInventors: Samuel C. Wadsworth, Donna Armentano, Richard J. Gregory, Geoffrey Parsons
-
Publication number: 20030147854Abstract: Gene Therapy vectors, which are especially useful for cystic fibrosis, and methods for using the vectors are disclosed.Type: ApplicationFiled: June 3, 2002Publication date: August 7, 2003Inventors: Richard J. Gregory, Donna Armentano, Larry A. Couture, Alan E. Smith
-
Publication number: 20030100526Abstract: The invention is directed to novel combinations of muscle-specific enhancer and promoter elements useful for achieving persistent expression in the muscle or myocytes. The muscle-specific promoter elements are derived from a muscle creatine kinase promoter, a troponin I promoter, a skeletal alpha-actin promoter, or a desmin promoter. The muscle-specific enhancer elements are derived from either troponin I internal regulatory elements, muscle creatine kinase enhancers, or desmin enhancers.Type: ApplicationFiled: May 24, 2002Publication date: May 29, 2003Inventors: David Souza, Donna Armentano
-
Publication number: 20030092162Abstract: The present invention provides chimeric adenoviral vectors that preferentially infect a target mammalian cell. Also provided are methods of targeting gene delivery to a specific cell type, treatment of cancer and methods of inducing a specific immune response in a subject. Pharmaceutical compositions are also provided.Type: ApplicationFiled: December 13, 2002Publication date: May 15, 2003Inventors: Srinivas Shankara, Donna Armentano, Bruce L. Roberts
-
Publication number: 20030017139Abstract: The invention is directed to novel combinations of liver specific enhancers and promoter elements for achieving persistent transgene expression in the liver. The liver specific enhancer elements may be derived from either the human serum albumin, prothrombin, &agr;-1microglobulin or aldolase genes in single copies or in multimerized form linked to elements derived from the cytomegalovirus intermediate early (CMV), &agr;-1-antitrypsin or albumin promoters. In a preferred embodiment of the invention, an adenoviral vector comprising a liver specific enhancer/promoter combination operably linked to a transgene is administered to recipient cells. In other embodiments of the invention, adeno-associated viral vectors, retroviral vectors, lentiviral vectors or a plasmid comprising the liver specific enhancer/promoter combination linked to a transgene is administered to recipient cells. Also within the scope of the invention are promoter elements derived from the human prothrombin gene and the &bgr;-fibrinogen gene.Type: ApplicationFiled: May 6, 2002Publication date: January 23, 2003Inventors: David W. Souza, Donna Armentano, Samuel C. Wadsworth
-
Patent number: 6485720Abstract: The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell.Type: GrantFiled: August 8, 2001Date of Patent: November 26, 2002Assignee: Genzyme CorporationInventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
-
Publication number: 20020164782Abstract: Gene Therapy vectors, which are especially useful for cystic fibrosis, and methods for using the vectors are disclosed.Type: ApplicationFiled: May 11, 2000Publication date: November 7, 2002Inventors: Richard J. Gregory, Donna Armentano, Larry A. Couture, Alan E. Smith
-
Publication number: 20020081707Abstract: The present invention provides methods and materials for the production of helper-dependent adenovirus, such as PAV, at high titers. In one embodiment, the invention comprises methods for producing high titers of helper-dependent adenovirus comprising co-transfecting a cell permissive for production of adenovirus with: (a) a helper-dependent adenoviral vector comprising inverted terminal repeats (ITRs) and packaging sequence derived from a first adenoviral serotype, and a transgene of interest flanked by said ITRs; and (b) a chimeric, packaging-deficient helper adenovirus which contains adenoviral genes derived from the first adenoviral serotype, packaging sequence derived from a second adenoviral serotype, and ITRs derived from either the first or second adenoviral serotypes; and collecting virions produced thereby.Type: ApplicationFiled: May 8, 2001Publication date: June 27, 2002Inventor: Donna Armentano
-
Patent number: 6358507Abstract: The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E40RF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E40RF3 and at least one other portion selected from E40RF4, E40RF6/7 and E40RF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell.Type: GrantFiled: October 12, 1999Date of Patent: March 19, 2002Assignee: Genzyme CorporationInventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
-
Publication number: 20020028194Abstract: The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell.Type: ApplicationFiled: August 8, 2001Publication date: March 7, 2002Inventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
-
Patent number: 6100086Abstract: The present invention relates to transgene expression systems, related pharmaceutical compositions, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA sequence encoding a transgene which codes for a desired product, expressibly contained within an adenovirus vector containing at least a portion of the E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or "E4 cassette") includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell. The transgene expression systems of the present invention are useful for a variety of applications including providing persistent cellular expression of the transgene in vitro and in vivo.Type: GrantFiled: April 14, 1997Date of Patent: August 8, 2000Assignee: Genzyme CorporationInventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory